Felipe Batalini, MD

Just out at @JCOPO_ASCO: we analyzed nearly 30K breast cancers and reported the specific frequencies of alterations in the HRD pathways. Also showed that somatic BRCA and germline PALB2 derive similar benefit to gBRCA @MayoClinic @BIDMChealth @DanaFarber ascopubs.org/doi/abs/10.120…

@Vinheteiro Jatos executivos da Embraer são os melhores do mundo. Líder em vendas.

Qual produto fabricado no Brasil é o melhor do mundo? Não conheço nenhum. Não é vinho, não é música, não é queijo, não é carro, não é eletrônico, não é chocolate, não é eletrodoméstico, não é arte, não é carne e não é fruta.

Many thanks to my wonderful colleagues from @BIDMChealth @NTungMD #GerburgWulf @DFCI_BreastOnc @judygarber5 and #FoundationMedicine @EthanSokol @geoff_oxnard @schrock_alexa et al

@hoje_no Se pensar bem, não é muito diferente do que acontece no Brasil e a corrupção do PT com nosso dinheiro que deveria servir a população.

Civis palestinos lançando pedras contra os terroristas do Hamas na Faixa de Gaza. Os terroristas estão saqueando os caminhões com ajuda humanitária que poucos minutos antes tinham entrado em Gaza a partir do Egito. Esse vídeo comprova as várias acusações de que os terroristas saqueiam os caminhões, retirando de lá tudo o que precisam, deixando para os civis apenas as migalhas. No final do vídeo vemos os civis correndo em direção aos caminhões, com os terroristas disparando os seus fuzis e fugindo com os caminhões cheios de ajuda humanitária.

@gilmarmendes Vocês do @STF_oficial são uma vergonha nacional. Defendem bandidos e não tem nenhum compromisso com o cidadão de bem, só com os companheiros.

(1/2) É com imensa alegria que recebo a notícia da indicação de Flávio Dino para o STF. Possuidor de vasta cultura jurídica e de inegável compromisso com o Estado Democrático de Direito, o indicado reúne plenas condições para exercer a jurisdição constitucional junto aos demais membros da Corte.

Our manuscript is out exploring real-world outcomes on PARPi in breast cancer. Patients with germline and somatic BRCA alterations have similar benefit (OS and PFS). A scar-based biomarker of HRD (HRDsig) is associated with favorable outcomes. ascopubs.org/doi/figure/10.…

@MelanieBriand @JAMAOnc @AshleyGWinter It would be a problem because you get it absorbed into the blood.

@JAMAOnc @AshleyGWinter What about women who used dermic oestrogen gel? Any stats?

This study found that women with breast cancer who used vaginal estrogen therapy (vaginal creams or vaginal tablets), compared with no hormone replacement therapy use, did not appear to have an increased risk of early breast cancer-specific mortality. ja.ma/3QpcVL2

Check out our new publication about PARPi in ovarian cancer cco.amegroups.com/article/view/1…. I’m so lucky to have met and worked with @FelipeBatalini and @laerciolopesMD who are such an inspiration to me. #LatinosInOncology

@KariWisinski_MD @AnthemBCBS It’s really a shame if @AnthemBCBS is not approving ribociclib for 1st line metastatic ER+HER2- breast cancer.

Why is @AnthemBCBS denying ribociclib for a patient with metastatic HR+/HER2 neg breast cancer? Denied despite an appeal letter. No answer when I call. Stop creating extra work for doctors. #priorauthreform

@Dr_RShatsky Yes, this is a big problem in Arizona as well. Patients being ripped off paying tens or hundreds of thousands of dollars for “alternative” treatments. Big scam!

How is it legal for someone with no formal oncology training (and no board certification in anything actually) to give chemotherapy to cancer patients. And why does the California Medical Board continue to allow this? #bcsm

The non-coding RNA miR-22 promotes EMT transition and metastasis in breast cancer. Inhibiting miR-22 with ASO suppressed mets and prolonged survival in mice. Thanks to collaborators and mentor @ivlacho for allowing me to help with the bioinformatics! pubmed.ncbi.nlm.nih.gov/37239141/

Pretty clear after @SABCSSanAntonio and @ASCO meetings that "HER2 low" is not a biological thing. HER2 0 and HER2 low tumors behave the same clinically. Serial testing shows that lots of HER2 1+/2+ are HER2 0 on later testing, or vice versa.

We’ll need to reconcile NATALEE and MonarchE. Different populations, side effect profile, and duration of therapies. Someone from the audience also brought up the estimated cost of half million dollars for the 3 years of adjuvant ribociclib. Abemaciclib probably not far behind.

We compared commercially available HRD biomarkers in terms of response to PARPi in ovarian cancer. BRCA respond the best, Myriad MyChoice and gLOH are comparable. HR proficient should not be on PARPi. Thanks to @laerciolopesMD @LetyCampoverde and others pubmed.ncbi.nlm.nih.gov/37211773/

I’m glad the FDA went back and made sure olaparib was approved only for the right patients with metastastic prostate cancer, THOSE WITH BRCA mutations. I’m sure we still missing other HRD alterations, so we will keep working on biomarkers.

Register now to attend @OncLive's Institutional Perspectives in Cancer virtual event for #BreastCancer, led by @MayoClinic experts @mpgoetz and @DrJudyBoughey. See the overview, featured topics and register here: mayocl.in/42vfnUB

On #MemorialDay, we remember those who lost their lives in service to our country. From the BCRF family to yours, wishing you a peaceful holiday weekend. Photo: Valentino Funghi/Unsplash

Final analysis of overall survival in ExteNET. After 8 years of follow up, there was no OS benefit with extended neratinib in the ITT, with an 8-year OS of 90% in both arms. A trend in better OS with neratinib is seen among HR+ patients (OS HR 0.80). ejcancer.com/article/S0959-…

@PTarantinoMD In real life, the benefit is only likely to be less, now that we all use T-DM1 for pts without a pathCR. I see very little role (perhaps none) for neratinib in the adjuvant setting.

@PTarantinoMD Yes, thanks for sharing these important OS data, a major need for pts with platinum-resistant ovarian cancer. It’s also nice to see biomarker-driven therapies: the folate receptor αlpha (FRα) in this case. We will need testing to become more widely available!!

ADCs keep improving outcomes for cancer patients. In the MIRASOL phase 3 trial, mirvetuximab soravtansine improved OS by nearly 4 months for patients with platinum-resistant ovarian cancer. cancernetwork.com/view/mirvetuxi…